Cover Image

Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma

Yongzhen Zhou,1,2,&ast; Chenjie Qiu,3,&ast; Qingsheng Fu,2 Tao Li,1 Xudong Zhang,1 Chunfu Zhu,1 Xihu Qin,1 Baoqiang Wu1,2 1Department of General Surgery, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, 213000, People's Republic of China; 2...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhou Y (Author), Qiu C (Author), Fu Q (Author), Li T (Author), Zhang X (Author), Zhu C (Author), Qin X (Author), Wu B (Author)
Format:	Book
Published:	Dove Medical Press, 2023-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma
by: Yunsheng Ran, et al.
Published: (2023)

Integrative Pan-Cancer Analysis Reveals the Oncogenic Role of MND1 and Validation of MND1’s Role in Breast Cancer
by: Zhang W, et al.
Published: (2024)

Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
by: Haofeng Lu, et al.
Published: (2022)

Multi-Omics Analysis and Verification of the Oncogenic Value of CCT8 in Pan-Cancers
by: Gong L, et al.
Published: (2023)

Exploring the oncogenic roles of LINC00857 in pan-cancer
by: Xiaomin Ren, et al.
Published: (2022)

Mechanisms of dihydromyricetin against hepatocellular carcinoma elucidated by network pharmacology combined with experimental validation
by: Shuo Zhang, et al.
Published: (2023)

Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker
by: Pan Xie, et al.
Published: (2022)

Integrating Network Pharmacology and Experimental Validation to Decipher the Mechanism of Action of Astragalus–Atractylodes Herb Pair in Treating Hepatocellular Carcinoma
by: Liang Y, et al.
Published: (2024)

PUS1 May Be a Potential Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma
by: Lan C, et al.
Published: (2023)

A pan-cancer analysis of oncogenic protein tyrosine phosphatase subfamily PTP4As
by: Mingyang Yu, et al.
Published: (2023)

circRASGRF2 functions as an oncogenic gene in hepatocellular carcinoma by acting as a miR-1224 sponge
by: Di Wu, et al.
Published: (2021)

SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma
by: Xing Jin, et al.
Published: (2021)

Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma
by: Mascha Mayer, et al.
Published: (2022)

Identification and Validation of Ferroptosis-Related Subtypes and a Predictive Signature in Hepatocellular Carcinoma
by: Zheng C, et al.
Published: (2023)

Integrating network pharmacology, bioinformatics, and experimental validation to unveil the molecular targets and mechanisms of galangin for treating hepatocellular carcinoma
by: Xiaoliang Li, et al.
Published: (2024)

Retraction Notice to: circRASGRF2 functions as an oncogenic gene in hepatocellular carcinoma by acting as a miR-1224 sponge
by: Di Wu, et al.
Published: (2024)

Integrating Network Pharmacology with in vitro Experiments to Validate the Efficacy of Celastrol Against Hepatocellular Carcinoma Through Ferroptosis
by: Cai B, et al.
Published: (2024)

RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
by: Claire JH Kramer, et al.
Published: (2023)

Correlation Between the RNA Methylation Genes and Immune Infiltration and Prognosis of Patients with Hepatocellular Carcinoma: A Pan-Cancer Analysis
by: Li XY, et al.
Published: (2022)

Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report
by: Wu Y, et al.
Published: (2023)

Predictive Efficacy of the Advanced Lung Cancer Inflammation Index in Hepatocellular Carcinoma After Hepatectomy
by: Qiu X, et al.
Published: (2024)

Computational design and validation of siRNA molecules to silence oncogenic CTNNB1 mRNA as a potential therapeutic strategy against hepatitis B/C virus-associated hepatocellular carcinoma
by: Lauren Emily Fajardo, et al.
Published: (2024)

Downregulation of ST6GAL1 Promotes Liver Inflammation and Predicts Adverse Prognosis in Hepatocellular Carcinoma
by: Liu R, et al.
Published: (2022)

An Integrative Analysis Identifying RAB40C as an Oncogenic Immune Protein and Prognostic Marker of Lung Squamous Cell Carcinoma
by: Wu H, et al.
Published: (2022)

AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma
by: Zhu Y, et al.
Published: (2019)

Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma: experimental findings and translational perspectives
by: Bimonte S, et al.
Published: (2019)

Pan-cancer analysis suggests histocompatibility minor 13 is an unfavorable prognostic biomarker promoting cell proliferation, migration, and invasion in hepatocellular carcinoma
by: Jun Liu, et al.
Published: (2022)

Acyl-CoA Binding Domain Containing 4 Polymorphism rs4986172 and Expression Can Serve as Overall Survival Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients After Hepatectomy
by: Huang H, et al.
Published: (2022)

Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score
by: Yongjiang Li, et al.
Published: (2022)

Integrating Network Pharmacology and Bioinformatics to Explore the Effects of Dangshen (Codonopsis pilosula) Against Hepatocellular Carcinoma: Validation Based on the Active Compound Luteolin
by: Yu Y, et al.
Published: (2023)

The EGFR Polymorphism Increased the Risk of Hepatocellular Carcinoma Through the miR-3196-Dependent Approach in Chinese Han Population
by: Zhang L, et al.
Published: (2021)

Prognostic role of ABO blood group in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization
by: Li Q, et al.
Published: (2018)

Identification of VRK1 as a Novel Potential Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
by: He X, et al.
Published: (2024)

Polyploidy Spectrum Correlates with Immunophenotype and Shapes Hepatocellular Carcinoma Recurrence Following Liver Transplantation
by: Zhang L, et al.
Published: (2022)

Pan-Cancer Analysis Reveals CENPI as a Potential Biomarker and Therapeutic Target in Adrenocortical Carcinoma
by: Wu F, et al.
Published: (2023)

Hepatic Artery Infusion Chemotherapy Sequential Hepatic Artery Embolization Combined with Operation in the Treatment of Recurrent Massive Hepatocellular Carcinoma Achieved Pathological Complete Response: A Case Report
by: Chen J, et al.
Published: (2023)

Morusin shows potent antitumor activity for human hepatocellular carcinoma in vitro and in vivo through apoptosis induction and angiogenesis inhibition
by: Gao L, et al.
Published: (2017)

Chronic Inflammatory and Immune Microenvironment Promote Hepatocellular Carcinoma Evolution
by: Chen S, et al.
Published: (2023)

The EGFR Polymorphism Increased the Risk of Hepatocellular Carcinoma Through the miR-3196-Dependent Approach in Chinese Han Population [Corrigendum]
by: Zhang L, et al.
Published: (2021)

Competing Endogenous RNA (ceRNA) Network Analysis of Autophagy-Related Genes in Hepatocellular Carcinoma
by: Yang C, et al.
Published: (2020)